Sepracor - Scientific Abstracts : LUNESTA® (eszopiclone)

AAN (American Academy of Neurology)
1. Pollack M, Kinrys G, Roth T, Rubens R, Schaefer K, Krystal A, McCall WV, Roach J, Huang H, Krishnan R. Evaluation of eszopiclone and escitalopram oxalate co-therapy in patients with generalized anxiety disorder and insomnia. Neurology 2007;6(12):A154 [Abstract]

2. Rubens R, Trick L, Roach J, Boyle J. The effects of a single evening dose of eszopiclone 3mg on next day driving ability and cognitive psychomotor function in patients with primary insomnia. Neurology 2007;6(12):A154 [Abstract]

AEP (Association of European Psychiatrists)
3. Bech P, Krystal A, Walsh J, Rubens R, Caron J, Wessel T, Amato D, Roth T, McCall WV, Fava M. Analysis of individual items of the Hamilton Depression Scale in a study of eszopiclone/fluoxetine co-therapy. Presented as a poster at the 15th European Congress of Psychiatry, March 17 - 21, 2007 (Abstract).

4. Montgomery S, Kinrys G, Krystal A, McCall WV, Roth T, Rubens R, Schaefer K, Roach J, Huang H, Krishnan R, Pollack M. Evaluation of eszopiclone and escitalopram oxalate co-therapy in patients with generalized anxiety disorder and insomnia. Presented as a poster at the 15th European Congress of Psychiatry, March 17 - 21, 2007 (Abstract).

5. Wessel T, Caron J, Trick L, Rubens R, Roach J, Boyle J. The effect of eszopiclone 3mg on next day driving ability and cognitive and psychomotor function in patients with primary insomnia. Presented as a poster at the 15th European Congress of Psychiatry, March 17 - 21, 2007 (Abstract).

AMCP (Academy of Managed Care Pharmacy Spring 2007)
6. Pollack M, Kinrys G, Krystal A, McCall V, Roth T, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R. Evaluation of eszopiclone and escitalopram oxalate co-therapy in patients with generalized anxiety disorder and insomnia. Journal of Managed Care Pharmacy 2007;13(2):182 [Abstract]

APA (American Psychiatric Association)
7. Boyle J, Rubens R, Roach J, Schaefer K, Johnsen S, Trick L. Next-day driving ability, cognition and psychomotor function following nighttime administration of eszopiclone in primary insomniacs. In New Research Abstracts, American Psychiatric Association 2007 Annual Meeting, San Diego, CA:263 [Abstract]

8. Fava M, Pollack M, Rubens R, Amato D, Krystal A, Hayduk R, McCall WV. Evaluation of the Hamilton Depression Scale following eszopiclone treatment for insomnia in patients with insomnia co-morbid with major depressive disorder or generalized anxiety disorder. In New Research Abstracts, American Psychiatric Association 2007 Annual Meeting, San Diego, CA:262 [Abstract]

9. Krystal A, Edinger J, Carney C, Amato D, Schaefer K, Rubens R, Fava M. Effects of eszopiclone/fluoxetine co-therapy on the percentage of patients experiencing coincident resolution of both insomnia and depression in patients with insomnia co-existing with major depressive disorder. In New Research Abstracts, American Psychiatric Association 2007 Annual Meeting, San Diego, CA:251 [Abstract]

10. McCall WV, Amato D, Schaefer K, Rubens R, Krystal A, Roth T, Walsh JK. Impact of four weeks' insomnia treatment on health-related quality of life in primary insomnia and insomnia co-morbid with major depressive disorder or rheumatoid arthritis. In New Research Abstracts, American Psychiatric Association 2007 Annual Meeting, San Diego, CA:251 [Abstract]

11. Pollack MH, Amato D, Schaefer K, Rubens R, Roach J, Krystal AD. Effects of eszopiclone/escitalopram co-therapy on the percentage of patients experiencing coincident resolution of both insomnia and anxiety in patients with insomnia co-existing with generalized anxiety disorder. In New Research Abstracts, American Psychiatric Association 2007 Annual Meeting, San Diego, CA:264 [Abstract]

12. Pollack MH, Kinrys GD, Krystal A, McCall WV, Roth T, Huang H, Krishnan RR. Evaluation of eszopiclone and escitalopram oxalate co-therapy in patients with insomnia and comorbid generalized anxiety disorder. In New Research Abstracts, American Psychiatric Association 2007 Annual Meeting, San Diego, CA:263 [Abstract]

APSS (Associated Professional Sleep Societies)
13. Amato D, McCall W, Roth T, Schaefer K, Rubens R, Wilson P, Walsh J. A comparison of nightly and weekly patient reports of sleep by insomniacs using integrated voice response system (IVRS). Sleep 2007;30(Suppl):A344 [Abstract]

14. Boyle J, Rubens R, Roach J, Johnsen S, Trick L. Next-day driving ability, cognition and psychomotor function following nighttime administration of eszopiclone in primary insomniacs. Sleep 2007;30(Suppl):A242 [Abstract]

15. Fava M, Pollack M, Rubens R, Amato D, Krystal A, Hayduk R, McCall W. Evaluation of the Hamilton Depression Scale following eszopiclone treatment for insomnia in patients with insomnia co-morbid with Major Depressive Disorder or Generalized Anxiety Disorder. Sleep 2007;30(Suppl):A329 [Abstract]

16. Krystal A, Fava M, Pollack M, Rubens R, Schaefer K, Amato D, Roth T. Sleep outcomes following eszopiclone discontinuation in patients with primary insomnia and insomnia co-existing with Major Depressive Disorder or Generalized Anxiety Disorder. Sleep 2007;30(Suppl):A245 [Abstract]

17. Kumar S, Alam M, Bashire T, McGinty D, Szymusiak R. Effects of the GABA-A agonist, eszopiclone, on sleep, body temperature and patterns of c-Fos expression in rats. Sleep 2007;30(Suppl):A46 [Abstract]

18. McCall W, Schaefer K, Rubens R, Huang H, Pfleeger K, Hayduk R, Roth T. Effects of eszopiclone co-therapy with escitalopram on sleep outcomes in patients with insomnia and comorbid Generalized Anxiety Disorder. Sleep 2007;30(Suppl):A330 [Abstract]

19. McCall WV, Galla J, Dunn A, Boggs N, Kimball J, Rosenquist P. Actigraphy measurement in depressed insomniacs. Sleep 2007;30(Suppl):A342 [Abstract]

20. Morin C, Schaefer K, Roach J, Pfleeger K, McCall W, Roth T. Baseline sleep impairment as assessed by the insomnia severity index I patients with primary insomnia and insomnia co-morbid with psychiatric or other physical disorders. Sleep 2007;30(Suppl):A245 [Abstract]

21. Moul D, Black B, Bankson L, Miewald J, Buysse D. The nocturnal sleep latency profile (NSLP): Preliminary data from patients with primary insomnia. Sleep 2007;30(Suppl):A239 [Abstract]

22. Pollack M, Rubens R, Amato D, Schaefer K, Pfleeger K, Hayduk R, Roth T. Effects of eszopiclone co-therapy with escitalopram on measures of anxiety and mood outcomes in patients with insomnia and comorbid Generalized Anxiety Disorder. Sleep 2007;30(Suppl):A330 [Abstract]

23. Roth T, Wilson P, Schaefer K, Rubens R, Walsh J, Krystal A. Baseline insomnia severity in patients with primary insomnia co-morbid with Major Depressive Disorder, Generalized Anxiety Disorder, perimenopausal transition or rheumatoid arthritis. Sleep 2007;30(Suppl):A247 [Abstract]

24. Rubens R, Wilson P, Schaefer K, McCall W, Roth T. Changes in sleep outcomes with placebo treatment in patients with primary insomnia and insomnia co-morbid with peri-menopausal transition or rheumatoid arthritis. Sleep 2007;30(Suppl):A247 [Abstract]

25. Schaefer K, McCall W, Krystal A, Rubens R, Wilson P, Pfleeger K, Roth T. Relative effect sizes of eszopiclone treatment for insomnia patients with primary insomnia and insomnia comorbid with Major Depressive Disorder, Generalized Anxiety Disorder, perimenopausal transition or rheumatoid arthritis. Sleep 2007;30(Suppl):A243 [Abstract]

26. Xi M, Ramos O, Chase M. Effects of eszopiclone on sleep and waking states in guinea pig. Sleep 2007;30(Suppl):A41 [Abstract]

27. Xi M, Ramos O, Chase M. Comparison of effects of eszopiclone and zolpidem on sleep and waking states in the guinea pig. Sleep 2007;30(Suppl):A42 [Abstract]

ASCPT (American Society for Clinical Pharmacology & Therapeutics)
28. Wang Z, Pentikis H, Maier G. A population phamacokinetic analysis for SEP-226330 in healthy subjects. Clin Pharm Ther 2007;81(Suppl):S40 [Abstract]

NCDEU (New Clinical Drug Evaluation Unit)
29. Fava M, Pollack M, Rubens R, Amato D, Krystal A, Hayduk R, McCall WV. Evaluation of the Hamilton Depression Scale following eszopiclone treatment for insomnia in patients with insomnia comorbid with major depressive disorder or generalized anxiety disorder. In Program Session Abstracts of the 47th Annual NCDEU meeting 2007:21 [Abstract]

30. McCall WV, Schaefer K, Rubens R, Huang H, Pfleeger K, Hayduk R, Roth T. Effects of eszopiclone co-therapy with escitalopram on sleep outcomes in patients with insomnia and comorbid generalized anxiety disorder. In Program Session Abstracts of the 47th Annual NCDEU meeting 2007:169 [Abstract]

31. Pollack M, Rubens R, Amato D, Schaefer K, Pfleeger K, Hayduk R, Roth T. Effects of eszopiclone co-therapy with escitalopram on measures of anxiety and mood outcomes in patients with insomnia and comorbid generalized anxiety disorder. In Program Session Abstracts of the 47th Annual NCDEU meeting 2007:174 [Abstract]

32. Reasner D, Wilson P, Amato D, Rubens R. The effect of threshold selection criteria on subsequent observations: A simulation study of HADS anxiety scale data. In Program Session Abstracts of the 47th Annual NCDEU meeting 2007:106 [Abstract]

33. Rubens R, Fava M, Amato D, Reasner D, Pfleeger K, Krystal A, McCall WV. Patient-reported versus clinician-rated evaluations of depression in a study of eszopiclone and fluoxetine co-therapy in patients with insomnia comorbid with major depressive disorder. In Program Session Abstracts of the 47th Annual NCDEU meeting 2007:170 [Abstract]

SOBP (Society of Biological Psychiatry)
34. Fava M, Pollack M, Rubens R, Amato D, Krystal A, Hayduk R, McCall WV. Evaluation of the Hamilton Depression Scale following eszopiclone treatment for insomnia in patients with insomnia comorbid with major depressive disorder or generalized anxiety disorder. Biological Psychiatry 2007;61(8S):84S [Abstract]

35. Krystal A, Fava M, Pollack M, Rubens r, Schaefer K, Amato D, Roth T. Sleep outcomes following eszopiclone discontinuation in patients with primary insomnia co-existing with major depressive disorder or generalized anxiety disorder. Biological Psychiatry 2007;61(8S):84S [Abstract]

36. Roth T, Wilson P, Schaefer K, Pfleeger K, Rubens R, Fava M, Pollack M. Insomnia severity in patients with primary insomnia and insomnia comorbid with major depressive disorder or generalized anxiety disorder. Biological Psychiatry 2007;61(8S):84S [Abstract]

37. Rubens R, McCall WV, Wilson P, Schaefer K, Fava M, Pollack M, Roth T. Changes in sleep outcomes with hypnotic placebo in patients with primary insomnia (PI) and insomnia comorbid with major depressive disorder (MDD) or generalized anxiety disorder (GAD). Biological Psychiatry 2007;61(8S):85S [Abstract]

2006 LUNESTA (eszopiclone) Abstracts

1. Amato D, Wilson P, Schaefer K, Rubens R. The relationship between eszopiclone's effects on sleep and depression in patients with new onset Major Depressive Disorder (MDD) and insomnia. Presented at the 158th Annual Meeting of the American Psychiatric Association 2006, Toronto, Ontario. (Abstract).

2. Amato D, Wilson P, Schaefer K, Rubens R. The relationship between eszopiclone's effects on sleep and depression in patients with new onset Major Depressive Disorder (MDD) and insomnia: surrogate marker analysis. SLEEP 2006, 29:A239 (Abstract).

3. Caron J, Wessel T, Rosenberg R, Rubens R, Boccagno J, Anderson A, Walsh JK. Four studies of eszopiclone in non-elderly and elderly patients with chronic insomnia. Presented at the Annual Meeting of the European Congress of Psychiatry, March 4 - 8, 2006, Nice, France. (Abstract).

4. Caron J, McCall V, Fava M, et al. Eszopiclone co-administered with fluoxetine for insomnia co-existing with Major Depressive Disorder (MDD): analysis by age. Presented at the 31st Annual Meeting of the Japanese Society of Sleep Research 2006. (Abstract).

5. Doghramji PP, Winkelman J, Rubens R et al. Evaluation of patient satisfaction: Regimen of Eszopiclone Sleep Satisfaction Trial (RESST). SLEEP 2006, 29:A250 (Abstract).

6. Krystal A, Rubens R, Fava M, McCall V, Wessel T, Roth T. Eszopiclone co-administered with fluoxetine for insomnia co-existing with Major Depressive Disorder (MDD): Effects following eszopiclone discontinuation. 158th Annual Meeting of the American Psychiatric Association 2006. (Abstract).

7. Krystal A, Walsh J, Rubens R et al. Efficacy and safety of six-months of nightly eszopiclone in patients with primary insomnia: a second long-term placebo-controlled study (Abstract). SLEEP 2006, 29, A249. (Abstract).

8. McCall WV, Fava M, Wessel T, Rubens R, Caron J, Amato D, Roth T. Co-administration of eszopiclone and fluoxetine in MDD & insomnia: depression effects. Presented at the Annual Meeting of the European Congress of Psychiatry. March 4 - 8, 2006, Nice, France. (Abstract).

9. McCall V, Krystal A, Fava M et al. Eszopiclone co-administered with fluoxetine for insomnia co-existing with Major Depressive Disorder (MDD): analysis by severity of insomnia (Abstract). SLEEP 2006, 29, A249. (Abstract).

10. McCall V, Krystal A, Rubens R et al. Two double-blind, placebo-controlled, 6-month trials of eszopiclone for insomnia: pooled analysis by race/ethnicity (Abstract). SLEEP 2006, 29, A249. (Abstract).

11. McCall V, Fava M, Wessel T, Rubens R, Caron J, Roth T. Eszopiclone co-administered with fluoxetine for insomnia co-existing with Major Depressive Disorder (MDD): Analysis by age. 158th Annual Meeting of the American Psychiatric Association. 2006. (Abstract).

12. Roth T, Schnitzer T, Rubens R, Wessel T, Caron J, Amato D. The effect of eszopiclone 3mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia. 158th Annual Meeting of the American Psychiatric Association 2006. (Abstract).

13. Roth T, Schnitzer T, Niewoehner J et al. The effect of eszopiclone 3mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia. Southern Sleep Society Annual Meeting 2006. (Abstract).

14. Rubens R, Roach J, Wessel T, Caron J, Amato D, Roth T. The effect of eszopiclone 3 mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia. Presented at the Annual Meeting of the American Academy of Pain Medicine, February 22 - 25, 2006, San Diego, CA. (Abstract).

15. Schnitzer T, Rubens R, Wessel T, Caron J, Amato D, Roth T. The effect of eszopiclone 3mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia. SLEEP 2006, 29, A238. (Abstract).

16. Soares CN, Joffe H, Rubens R, Amato D, Roach J, Caron J. Eszopiclone treatment during menopausal transition: sleep effects, impact on menopausal symptoms and mood. 158th Annual Meeting of the American Psychiatric Association 2006. (Abstract).

17. Soares CN, Rubens R, Caron J et al. Eszopiclone treatment during menopausal transition: sleep effects, impact on menopausal symptoms and mood. SLEEP 2006, 29, A239. (Abstract).

18. Soares CN, Joffe H, Skolly S et al. Eszopiclone treatment during menopausal transition: sleep effects, impact on menopausal symptoms and mood. Southern Sleep Society Annual Meeting . 2006. (Abstract).

19. Soares CN, Utian W, Rubens R, Amato D, Roach J, Cohen LS. Evaluation of eszopiclone 3 mg in the treatment of insomnia associated with the menopausal transition. Obstet Gynecol 2006, 107(4 Suppl):24S. (Abstract).

20. Wessel T, Roth T, Krystal A, Caron J, Amato D. Twelve months of nightly eszopiclone treatment in patients with chronic insomnia: assessment of long-term efficacy and safety. Presented at the Annual Meeting of the European Congress of Psychiatry, March 4 - 8, 2006, Nice, France. (Abstract).

21. Wessel T, Krystal A, Walsh J et al. Evaluation of the efficacy and safety of eszopiclone over six-months of treatment in patients with insomnia. 31st Annual Meeting of the Japanese Society of Sleep Research 2006. (Abstract).

2005 LUNESTA (eszopiclone) Abstracts

1. Allen SM, Rosenberg R, Rubens R. Four eszopiclone studies in elderly and non-elderly chronic insomniacs. Presented at the Southern Sleep Society Annual Meeting, March 31 - April 3, 2005, New Orleans, LA (Abstract).

2. Amato D, McCall WV, Schaefer K, Rubens R. Effect of eszopiclone on sleep parameters that affect next day function. In: Program and abstracts of the 158th Annual Meeting of the American Psychiatric Association, May 21 - 26, 2005, Atlanta, GA NR556 (Abstract).

3. Amato D, Buysse D, Wilson P. Trajectory analysis of treatment response across a twelve-month study of nightly eszopiclone in patients with chronic insomnia. SLEEP 2005; 28(Suppl):A239 (Abstract).

4. Anderson A, Maier G, Skolly S. Pharmacokinetic interaction of eszopiclone and ketoconazole in healthy subjects. Pharmacotherapy 2005, 25(3):474 (Abstract).

5. Anderson A, Skolly S, Maier G. Evaluation of a pharmacokinetic interaction between eszopiclone and digoxin. International Pharmaceutical Abstracts 2005, 39:363e. (Abstract).

6. Anderson AJ, Maier G, Skolly SM. Pharmacokinetic interaction between eszopiclone and ketoconazole in healthy volunteers at steady state. In: Program and Abstracts of Senior Care Pharmacy 2005; American Society of Consultant Pharmacists 36th Annual Meeting, November 9 - 12, 2005, Boston, MA. Pg 100 (Abstract).

7. Anderson AJ, Roach J, Rosenberg R, Scharf M, Wilson P. Evaluation of eszopiclone in patients with obstructive sleep apnea. In: Program and Abstracts of Senior Care Pharmacy 2005; American Society of Consultant Pharmacists 36th Annual Meeting, November 9 - 12, 2005, Boston, MA. (Abstract).

8. Anderson AJ, McCall WV, Niewoehner J, Rubens R, Amato D. A pooled analysis of the safety and efficacy of eszopiclone in the treatment of primary insomnia in the elderly. In: Program and Abstracts of Senior Care Pharmacy 2005; American Society of Consultant Pharmacists 36th Annual Meeting, November 9 - 12, 2005, Boston, MA. Pg 93 (Abstract).

9. Botteman MF, Ozminkowski RJ, Wang S, Pashos C, Foley DJ, Schaefer K. Cost effectiveness of long-term treatment with eszopiclone 3 mg in adults with primary insomnia. Value in Health 2005; 8(3):323 (Abstract).

10. Buysse D, McCall WV, Rubens R, Wessel T, Wilson P, Caron J, Roth T. Adjunctive eszopiclone with fluoxetine for MDD and insomnia; sleep effects. In: Program and abstracts of the 158th Annual Meeting of the American Psychiatric Association, May 21 - 26, 2005, Atlanta, GA NR558 (Abstract).

11. Buysse D, McCall WV, Roach J, Wessel T, Wilson P, Caron J, Roth T. Eszopiclone co-administered with fluoxetine for insomnia associated with Major Depressive Disorder (MDD): sleep effects. SLEEP 2005; 28(Suppl):A311 (Abstract).

12. Buysse D, McCall WV, Rubens R, Wessel T, Durrence HH, Wilson P, Allen S, Caron J, Roth T. Adjunctive eszopiclone with fluoxetine for MDD and insomnia: sleep effects. Presented at the 57th Institute on Psychiatric Services, October 5 - 9, 2005, San Diego, CA (Abstract).

13. Corrigan M, McCall WV, Fava M, Rubens R, Wessel T, Caron J, Amato D, Roth T. Adjunctive eszopiclone and fluoxetine in Major Depressive Disorder in insomnia: effects on sleep and depression. Neuropsychopharmacology 2005; 30(S1):S104 (Abstract).

14. Corrigan M, McCall WV, Fava M, Buysse DJ, Rubens R, Wessel T, Caron J, Amato D, Roth T. Adjunctive eszopiclone and fluoxetine in Major Depressive Disorder and insomnia: Effects on sleep and depression. Presented at the Annual Meeting of the World Federation of Sleep Research and Sleep Medicine Societies 2005, New Delhi, India (Abstract).

15. Eng PM, Ziyadeh N, Nordstrom BL, Caron J, Amato D, Seeger JD. Incidence of selected outcomes among matched cohorts of initiators of racemic zopiclone, temazepam, and zolpidem in the general practice research database. Pharmacoepidemiology and Drug Safety 2005, 14(S2):s22-s23. (Abstract).

16. Eng PM, Ziyadeh N, Nordstrom BL, Caron J, Amato D, Seeger JD. Matched retrospective cohort study of breast cancer incidence among initiators of racemic zopiclone, temazepam, and zolpidem in the general practice research database. Pharmacoepidemiology and Drug Safety 2005, 14(S2):s162. (Abstract).

17. Erman MK, Walsh JK, Wessel T, Caron J, Amato D. A crossover study of eszopiclone in the treatment of primary insomnia. In: Program and abstracts of the 158th Annual Meeting of the American Psychiatric Association, May 21 - 26, 2005, Atlanta, GA NR555 (Abstract).

18. Erman MK, Walsh JK, Wessel T, Caron J, Amato DA. A dose-response efficacy and safety study of eszopiclone in the treatment of primary insomnia. SLEEP 2005; 28(Suppl):A237 - A238 (Abstract).

19. Erman MK, Walsh JK, Durrence HH, Wessel T, Caron J, Amato D. A crossover study of eszopiclone in the treatment of primary insomnia. Presented at the 57th Institute on Psychiatric Services, October 5 - 9, 2005, San Diego, CA (Abstract).

20. Fava M, Buysse D, Rubens R, Wessel T, Caron J, Roth T. Eszopiclone co-administrered with fluoxetine for insomnia associated with major depressive disorder (MDD): effects on sleep and depression. In: Program and Abstracts of New Clinical Drug Evaluation Unit Annual Meeting, June 6 - 9, 2005, Boca Raton, FL p. 308 (Abstract).

21. Krystal A, Rubens R, Fava M, McCall WV, Wessel T, Amato D, Caron J, Roth T. Eszopiclone co-administered with fluoxetine for insomnia associated with major depressive disorder (MDD): effects following eszopiclone discontinuation. SLEEP 2005; 28(Suppl):A311 (Abstract).

22. Krystal A, Walsh JK, Roth T, Rubens R, Wilson P, Niewoehner J, Wessel T. Evaluation of the efficacy and safety of eszopiclone over six months of treatment in patients with insomnia. Pharmacotherapy 2005;25(10):1505 (Abstract).

23. Krystal A, Walsh J, Roth T, Rubens R, Wessel T. Efficacy and safety of six-months of nightly eszopiclone in patients with primary insomnia. Annals of Neurology 2005;(Suppl 9):S67 (Abstract).

24. Krystal A, Walsh JK, Roth T, Anderson A, Rubens R, Wilson Ph, Wessel T. Evaluation of the efficacy and safety of eszopiclone over six months of treatment in patients with insomnia. Presented at the 57th Institute on Psychiatric Services, October 5 - 9, 2005, San Diego, CA (Abstract).

25. McCall WV, Fava M, Wessel T, Rubens R, Caron J, Amato D, Roth T. Adjunctive eszopiclone and fluoxetine in MDD & insomnia: depression effects. In: Program and abstracts of the 158th Annual Meeting of the American Psychiatric Association, May 21 - 26, 2005, Atlanta, GA NR557 (Abstract).

26. McCall WV, Fava M, Wessel T, Rubens R, Caron J, Amato D, Roth T. Eszopiclone co-administered with fluoxetine for insomnia associated with Major Depressive Disorder (MDD): an analysis of the effects on depression. SLEEP 2005; 28(Suppl):A310 (Abstract).

27. McCall WV, Fava M, Buysse DJ, Rubens R, Wessel T, Caron J, Amato D, Anderson A, Roth T. Adjunctive eszopiclone and fluoxetine in Major Depressive Disorder and insomnia: effects on sleep and depression. Pharmacotherapy 2005; 25(10):1511 (Abstract).

28. McCall WV, Schaefer K, Fava M, Wessel T, Rubens R, Caron J, Amato D, Roth T. Adjunctive eszopiclone and fluoxetine in MDD and insomnia: depression effects. Presented at the 57th Institute on Psychiatric Services, October 5 - 9, 2005, San Diego, CA (Abstract).

29. Niewoehner JW, Krystal A, Roach J, Caron J. Efficacy of eszopiclone in the treatment of sleep maintenance insomnia: a subset analysis by baseline wake time after sleep onset (WASO). Presented at the Southern Sleep Society Annual Meeting, March 31 - April 3, 2005, New Orleans, LA (Abstract).

30. Ozminkowski R, Lenhart G, Wang S, Barry N, Rubens R, Schaefer K, Anderson A. Using medical claims data and published literature to predict impact of formulary addition of a new anti-insomnia agent. Pharmacotherapy 2005, 25(3):471 (Abstract).

31. Ozminkowski R, Lenhart G, Wang S, Mucha L, Barry N, Schaefer K, Rubens R. Using medical claims data and clinical literature to forecast the impact of adding a new drug onto the formulary: a case study of insomnia treatment. Journal of Managed Care Pharmacy 2005; 11(3):284 (Abstract).

32. Ozminkowski R, Lenhart G, Wang S, Barry N, Schaefer K, Mucha L. Using medical claims data and clinical literature to forecast the impact of adding a new drug onto the formulary: a case study of insomnia treatment. SLEEP 2005; 28(Suppl):A239 (Abstract).

33. Ozminkowski R, Lenhart G, Wang S, Barry N, Schaefer K, Mucha L, Rubens R. Forecasting the impact of adding a new drug on formulary using medical claims data and clinical literature: a case study of insomnia treatment. Value in Health 2005: 8(3):323 (Abstract).

34. Roach J, Rosenberg R, Scharf M, Wilson P. Evaluation eszopiclone (ESZ) in patients with obstructive sleep apnea (OSA). Proceedings of the American Thoracic Society 2005; 2:A65 (Abstract).

35. Rosenberg R, Scharf M, Wilson P, Roach J. Evaluation of the safety and efficacy of eszopiclone in patients with obstructive sleep apnea. SLEEP 2005; 28(Suppl):A154 (Abstract).

36. Rubens R, Krystal A, Wessel T, Roth T, Caron J, Amato D. Efficacy of eszopiclone in the treatment of sleep maintenance insomnia. Neurology 2005, 64(6)Suppl 1:A46 (Abstract).

37. Schnitzer T, Rubens R, Price J, Wessel T, Caron J, Amato D, Roth T. The effect of eszopiclone 3mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia. Arthritis and Rheumatism 2005;52(9):S352 (Abstract).

38. Skolly S, Erman MK, Wessel T. Consistency of patient-reported measures of efficacy and next day function of eszopiclone in adults with chronic insomnia treated with eszopiclone 3 mg. Presented at the Southern Sleep Society Annual Meeting, March 31 - April 3, 2005, New Orleans, LA (Abstract).

39. Soares C, Rubens R, Amato D, Roth T, Caron J, Skolly SM, Wessel T. Evaluation of eszopiclone 3mg in the treatment of insomnia associated with menopausal transition. Pharmacotherapy 2005; 25(10):1518 (Abstract).

40. Soares C, Rubens R, Amato D, Roth T, Caron J, Mariani R, Wessel T. Evaluation of eszopiclone 3 mg in the treatment of insomnia associated with menopausal transition. Presented at the 57th Institute on Psychiatric Services, October 5 - 9, 2005, San Diego, CA (Abstract).

41. Wessel T, Roth T, Krystal A, Caron J, Amato D. Twelve months of nightly eszopiclone treatment in patients with chronic insomnia: assessment of long-term efficacy and safety. Neurology 2005; 64(6)Suppl 1:A46 (Abstract).

42. Wessel T, Rubens R, Toth T, Krystal S, Walsh JK, Caron J, Amato D, Anderson AJ. Twelve months of nightly eszopiclone treatment in patients with chronic insomnia: assessment of long-term efficacy and safety. Presented at the 30th Annual Meeting of the Japanese Society of Sleep Research, Utsunomiya, Japan, June 30 - July 1, 2005 (Abstract).

43. Wessel T, Erman MK, Walsh JK, Caron J, Amato D, Anderson AJ. A dose-response efficacy and safety study of eszopiclone in the treatment of primary insomnia. Presented at the 30th Annual Meeting of the Japanese Society of Sleep Research, Utsunomiya, Japan, June 30 - July 1, 2005 (Abstract).

44. Wessel T, Maier G, Rubens R, Amato D, Boccagno J, Anderson A. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of eszopiclone: a comparison of healthy non-elderly and elderly adults. Presented at the 30th Annual Meeting of the Japanese Society of Sleep Research, Utsunomiya, Japan, June 30 - July 1, 2005 (Abstract).

45. Wessel T, Rosenberg R, Rubens R, Boccagno J, Anderson AJ, Walsh JK. Four studies of eszopiclone in non-elderly and elderly patients with chronic insomnia. Presented at the 30th Annual Meeting of the Japanese Society of Sleep Research, Utsunomiya, Japan, June 30 - July 1, 2005 (Abstract).

2004 LUNESTA (eszopiclone) Abstracts

1. Anderson A, Skolly S, Maier G. Evaluation of a pharmacokinetic interaction between eszopiclone and digoxin. Pharmacotherapy 2004; 24(10):1420. (Abstract).

2. Anderson A, McCall V, Rubens R. Efficacy and safety study of eszopiclone treatment in elderly adults with chronic insomnia. In: Program and Abstracts of Senior Care Pharmacy 2004; American Society of Consultant Pharmacists' 35th Annual Meeting, November 3-6, 2004, San Francisco, CA. p.90. (Abstract).

3. Buysse D, Wilson P, Amato D, Wessel T. Trajectory analysis of treatment response during a six-month study of nightly eszopiclone in patients with chronic insomnia. In: program and Abstracts of New Clinical Drug Evaluation Unit Annual Meeting, June 1 - 4, 2004, Phoenix, AZ p.323 (Abstract).

4. Krystal A, Roach J, Caron J, Rubens R, Anderson A. The use of eszopiclone in the treatment of sleep maintenance insomnia: a subset analysis of efficacy by baseline wake time after sleep onset (WASO). Pharmacotherapy 2004; 24(10):1465. (Abstract).

5. Krystal A, Roach J, Caron J, Durrence H. Efficacy of eszopiclone in the treatment of Sleep maintenance insomnia. Presented at the 56th Institute on Psychiatric Services, October 6 - 10, 2004, Atlanta, GA (Abstract).

6. McCall V. A study of eszopiclone 2mg in elderly patients with chronic insomnia (Abstract). American Journal of Geriatric Psychiatry 2004, 12:(Abstract).

7. McCall WV, Rosenberg R, Caron J, Durrence H. Polysomnographic evaluation of the efficacy and safety of eszopiclone in elderly subjects with chronic insomnia. Presented at the 56th Institute on Psychiatric Services, October 6 - 10, 2004, Atlanta, GA (Abstract).

8. Niewoehner J, Anderson A, Maier G. Pharmacokinetic and pharmacodynamic interaction of eszopiclone and lorazepam in healthy subjects. Pharmacotherapy 2004; 24(10):1421. (Abstract).

9. Ozminkowski RJ, Wang S, Orsini L, Schaefer K, Anderson A, Barry N, Albert E. Estimating the cost burden of insomnia in elderly and non-elderly adults. Pharmacotherapy 2004; 24(10):1456. (Abstract).

10. Ozminkowski RJ, Wang S, Trautman HC, Orsini L. Estimating the cost burden of insomnia for health plans. Presented at the Annual Meeting of the Academy of Managed Care Pharmacy 2004, Baltimore, MD. (Abstract).

11. Rosenberg R, Rubens R, Niewoehner J. Four studies of eszopiclone in non-elderly and elderly patients with chronic insomnia. Pharmacotherapy 2004; 24(10):1464. (Abstract).

12. Rosenberg R, Rubens R, DeMoranville V. Four studies of eszopiclone in non-elderly and elderly patients with chronic insomnia. Presented at the 56th Institute on Psychiatric Services, October 6 - 10, 2004, Atlanta, GA (Abstract).

13. Roth T, Krystal A, Walsh J, Wessel T, Roehrs T, Caron J, Amato D, Skolly S. Twelve months of nightly eszopiclone treatment in patients with chronic insomnia: assessment of long-term efficacy and safety. Pharmacotherapy 2004; 24(10):1464. (Abstract).

14. Roth T, Krystal A, Wessel T, Caron J, Durrence H. An assessment of the long-term efficacy and safety of eszopiclone over twelve months of nightly treatment in patients with chronic insomnia. Presented at the 56th Institute on Psychiatric Services, October 6 - 10, 2004, Atlanta, GA (Abstract).

15. Rubens R, Wessel T. A six week efficacy and safety study of eszopiclone in adults with chronic insomnia (Abstract). Neurology 2004; 62(Suppl):A59-A60. (Abstract).

16. Rubens R, Caron J, Gottlieb RH. Six-month efficacy of eszopiclone in women with chronic insomnia. Obstet Gynecol 2004; 103(4)Suppl:122S. (Abstract).

17. Soares CN, Caron J, Schaefer K, Rubens R, Gottlieb RH. Six-month efficacy study of eszopiclone in perimenopausal and postmenopausal women with chronic insomnia. Obstet Gynecol 2004; 103(4)Suppl:102S (Abstract).

18. Skolly S, Niewoehner J, Maier G. Pharmacokinetic and pharmacodynamic interaction of eszopiclone and paroxetine in healthy subjects. Pharmacotherapy 2004; 24(10):1422. (Abstract).

19. Tarantino P, Rubens R. Effects of Trazodone on hERG channel current. Presented at the Annual Meeting of the American Academy of Family Physicians 2004, Orlando, FL (Abstract).

20. Wessel T, Rubens R. A study of eszopiclone 2 mg in elderly patients with chronic insomnia (Abstract). Neurology 2004; 62(Suppl):A60. (Abstract).

2003 LUNESTA (eszopiclone) Abstracts

1. Maier G, Hsu B, M, Russell T, Levasseur L. Evaluation of eszopiclone permeability using the caco-2 in vitro model (Abstract). PharmSci 2003;5:T2127

2. Maier G, Koch P, Caron J, Amato D, Britto M, Russell T, Levasseur L. Dose proportionality and time to steady-state of eszopiclone in healthy adult volunteers following single and multiple dosing (Abstract). Pharm Sci 2003;5:M1325

3. Rowlett JK, Lelas S. Abuse-related effects of benzodiazepine-type hypnotics in monkeys (abstract). Presented at the Society for Neuroscience Annual Meeting, November 2003.

4. Scharf M, Seiden D, Erman M, Rosenberg R, McCall V, Wessel T. Eszopiclone rapidly induced Sleep and provided Sleep maintenance in elderly patients with chronic insomnia (Abstract). International Psychogeriatrics 2003;15(2):200-201

5. Walsh KA, Roth T, Amato DA, Wessel T. The sustained efficacy and safety of eszopiclone over six months of nightly treatment: a placebo-controlled study in patients with chronic insomnia (Abstract). SLEEP 2003;26:A310

6. Zammit GK, Gillin JC, McNabb L, Caron J, Roth T. Eszopiclone, a novel non-benzodiazepine anti-insomnia agent: a six-week efficacy and safety study in adult patients with chronic insomnia (Abstract). SLEEP 2003;256:A297

2002 LUNESTA (eszopiclone) Abstracts

1. Leese P, Maier G, Vaickus L, Akylbekova E. Eszopiclone: pharmacokinetic and pharmadynamic effects of a novel sedative hypnotic after daytime administration in healthy subjects (abstract). SLEEP 2002;25:A45.

2. Rosenberg RP, Jamieson A, Vaickus L, Roth T. Eszopiclone, a novel non-benzodiazepine sedative-hypnotic: efficacy and safety in a model of transient insomnia (Abstract). SLEEP 2002;45:A68-69